Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R)

Cardiovascular Revascularization Medicine

Volumn 17, Issue 1, 2016, Pages 34-37

  Nef, Holger ^a   Wiebe, Jens ^a   Achenbach, Stefan ^b   Münzel, Thomas ^c   Naber, Christoph ^d   Richardt, Gert ^e   Mehilli, Julinda ^f   Wöhrle, Jochen ^g   Neumann, Till ^h   Biermann, Janine ^h   Zahn, Ralf ⁱ   Kastner, Johannes ^j   Schmermund, Axel ^k   Pfannebecker, Thomas ^l   Schneider, Steffen ^m   Limbourg, Tobias ^m   Hamm, Christian W ^a,n  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ELISABETH KRANKENHAUS ESSEN   (Germany)

^e Segeberger Kliniken GmbH   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁱ KLINIKUM LUDWIGSHAFEN   (Germany)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k CARDIOANGIOLOGISCHES CENTRUM BETHANIEN   (Germany)

^l ABBOTT GMBH AND CO KG   (Germany)

^m Institut fuer Herzinfarktforschung   (Germany)

ⁿ Kerckhoff Heart and Thorax Center   (Germany)

more..

Author keywords

Bioresorbable scaffolds; BVS; Coronary artery disease; Stenosis

Indexed keywords

EVEROLIMUS; POLYLACTIC ACID;

ARTICLE; AUSTRIA; BIORESORBABLE VASCULAR STENT; CORONARY ARTERY OBSTRUCTION; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; GERMANY; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; SAFETY; TREATMENT OUTCOME; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY STENOSIS; DRUG ELUTING STENT; METHODOLOGY;

ABSORBABLE IMPLANTS; AUSTRIA; COHORT STUDIES; CORONARY STENOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; GERMANY; HUMANS; PROSPECTIVE STUDIES; REGISTRIES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84959121506     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2015.09.002     Document Type: Article

References (18)

1. Palmerini T., Biondi-Zoccai G., Della Riva D., Stettler C., Sangiorgi D., D'Ascenzo F., et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012, 379:1393-1402.
2. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schomig A., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
3. Stone G.W., Rizvi A., Newman W., Mastali K., Wang J.C., Caputo R., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010, 362:1663-1674.
4. Authors/Task Force m, Windecker S., Kolh P., Alfonso F., Collet J.P., Cremer J., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014, 35:2541-2619.
5. Wiebe J., Nef H.M., Hamm C.W. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol 2014, 64:2541-2551.
6. Puricel S., Arroyo D., Corpataux N., Baeriswyl G., Lehmann S., Kallinikou Z., et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015, 65:791-801.
7. Serruys P.W., Chevalier B., Dudek D., Cequier A., Carrie D., Iniguez A., et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015, 385:43-54.
8. Abizaid A., Ribamar Costa J., Bartorelli A.L., Whitbourn R., van Geuns R.J., Chevalier B., et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 2015, 10:1396-1401.
9. Capodanno D., Gori T., Nef H., Latib A., Mehilli J., Lesiak M., et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015, 10:1144-1153.
10. Wiebe J., Mollmann H., Most A., Dorr O., Weipert K., Rixe J., et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol 2014, 103:141-148.
11. Wohrle J., Naber C., Schmitz T., Schwencke C., Frey N., Butter C., et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2015, 11:149-156.
12. Otsuka F., Pacheco E., Perkins L.E., Lane J.P., Wang Q., Kamberi M., et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv 2014, 7:330-342.
13. Vorpahl M., Nakano M., Perkins L.E., Otsuka F., Jones R., Acampado E., et al. Vascular healing and integration of a fully bioresorbable everolimus-eluting scaffold in a rabbit iliac arterial model. EuroIntervention 2014, 10:833-841.
14. Finn A.V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M.C., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
15. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
16. Brugaletta S., Heo J.H., Garcia-Garcia H.M., Farooq V., van Geuns R.J., de Bruyne B., et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?. Eur Heart J 2012, 33:1325-1333.
17. Ormiston J.A., Serruys P.W., Onuma Y., van Geuns R.J., de Bruyne B., Dudek D., et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 2012, 5:620-632.
18. Serruys P.W., Onuma Y., Dudek D., Smits P.C., Koolen J., Chevalier B., et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011, 58:1578-1588.